products that have half-lives of around 12 hours. 4 Despite the longterm benefits of prophylaxis in preventing arthropathy, the burden of treatment is a major barrier to adherence in patients with hemophilia A. 5 To address the burden of frequent dosing, long-acting recombinant FVIII (rFVIII) products have been developed with improved pharmacokinetic properties with the aim of reducing the dosing frequency while minimizing the risk of bleeding. 6, 7 rVIII-SingleChain (AFSTYLA ® , CSL Behring) is a novel rFVIII product engineered with a covalent bond between the heavy and light chains to increase molecular stability and was designed to have high binding affinity for von Willebrand factor (VWF). 8 rVIII-SingleChain has a 35% higher AUC and a 29% lower clearance than octocog alfa (ADVATE ® , Takeda). 9 Patients treated with rVIII-SingleChain can be dosed 2-3 times a week, allowing some patients to be dosed less frequently compared with standard-acting products, while also maintaining high FVIII activity levels 6, 10 ; this may enhance convenience and adherence to therapy. Clinical trials have demonstrated that rVIII-Sin-gleChain is suitable for the control and prevention of bleeding episodes and has an excellent safety profile in adults/adolescents and children. 6, 10 The increased number of available FVIII products means that there is an expanding choice of products for patients; it is therefore critical to identify the product(s) that can provide the greatest overall benefit, both clinically and economically. No direct head-tohead studies have been conducted to compare efficacy and safety of rFVIII products in hemophilia A.
Here, we investigated real-world use of rVIII-SingleChain (AFSTYLA ® ) and four other commonly used rFVIII products: rFVIIIFc (Elocta ® , Sobi), octocog alfa (rFVIII, ADVATE ® , Takeda), octocog alfa (BAY 81-8973, Kovaltry ® , Bayer), and moroctocog alfa (ReFacto ® , Pfizer) in hemophilia A patients treated prophylactically in Germany.
In these patients, we assessed bleeding rates, dosing frequency, and factor consumption. In addition, clinical outcomes in patients currently receiving prophylaxis with rVIII-SingleChain were compared with their prior FVIII product.
| ME THODS

| Cohort analysis
A retrospective review of de-identified patient chart data was obtained from pre-existing medical records from 21 Hemophilia Treatment Centers (HTCs) across Germany. In this cohort study, males diagnosed with hemophilia A currently using one of five commonly prescribed rFVIII products for prophylaxis: rVIII-Single-Chain, rFVIIIFc, octocog alfa (rFVIII), octocog alfa (BAY 81-8973), or moroctocog alfa were included; a minimum of 8 weeks of prophylaxis treatment were required for patients to be included in the analysis. The study was submitted to an institutional review board and was determined to be exempt under category 4 "Secondary research for which consent is not required." Data were collected from August to November 2018. Where possible, patient selection took into account age and disease severity in order to balance these characteristics among the patient groups using these products.
Data pertaining to patient demographics and characteristics, treatment, and clinical outcomes were collected, including: age, weight, sex, severity of hemophilia A, duration on FVIII product, dosing (dose and frequency) of FVIII products, and number of spontaneous and traumatic bleeds reported over a period of up to 12 months. Both adult/adolescent and pediatric patients were included; for the purposes of this study, patients ≥12 years were defined as adults/adolescents, and patients <12 years were defined as pediatrics. Furthermore, disease severity in hemophilia patients with <1% of normal FVIII blood levels was defined as severe, 1-≤5% was defined as moderate, and >5% was defined as mild.
Data were analyzed for patients with severe disease as well as for all patients using one of the rFVIII products, and comparisons were made between the products. The primary outcome measures were annualized bleed rates (ABR) and FVIII consumption.
Bleeding rates were annualized by dividing the number of bleeding events by the number of months in the reported time window 
Novelty statements
• What is the new aspect of your work? This is the first study evaluating the clinical outcome and utilization of a range of FVIII products using real-world data in Germany.
• What is the central finding of your work? rVIII-SingleChain may lead to lowest factor consumption among the five FVIII products assessed while providing excellent bleeding protection with comparable bleeding rates and also demonstrates effective bleed prevention in patients who switched to rVIII-SingleChain prophylaxis, allowing the majority of patients to be treated on a 2×/week regimen.
• What is (or could be) the specific clinical relevance of your work?
Patients with hemophilia, including those with severe disease, can be dosed less frequently using rVIII-SingleChain compared with standard-acting products, which may reduce the burden of treatment and factor consumption.
| Switch analysis
Further analysis of patients described in the cohort analysis above who were receiving prophylaxis with rVIII-SingleChain was conducted.
Data were collected about the products they used before switching to rVIII-SingleChain and ABR, dosing frequency, and factor consumption were then compared between rVIII-SingleChain and prior products.
| Statistical methods
Analysis of covariance (ANCOVA) was used to assess the statistical significance of differences in mean ABR and FVIII consumption between the different cohorts of patients. The ANCOVA model used to assess mean ABR differences included age, weight, severity, and consumption as covariates, whereas the model used to assess FVIII consumption included age, weight, and severity. The statistical significance of the differences in proportion of patients with zero bleeds across products was assessed using Fisher's exact test.
For the switch analysis, paired t-test were used to evaluate the statistical significance of the differences in mean ABR and FVIII consumption while on rVIII-SingleChain vs prior products. McNemar's test was used to assess the statistical significance of the difference in proportion of patients with zero bleeds between rVIII-SingleChain and prior products.
| RE SULTS
| Cohort analysis
A total of 21 HTCs across Germany provided data for 225 male patients, with patients using rVIII-SingleChain (n = 40), rFVIIIFc (n = 47), octocog alfa (rFVIII; n = 58), octocog alfa (BAY 81-8973; n = 40), or moroctocog alfa (n = 40); patient characteristics are described ( Table 1) .
The majority of patients in each cohort were adults, and among all patients, 33.8% had severe disease. In patients with severe disease, a high proportion were dosing ≤2×/week with rVIII-SingleChain or rFVII-IFc (66.6% and 70.0%, respectively), whereas the majority of patients using standard-acting products were dosed 3×/week (octocog alfa
[rFVIII], 60.0%; octocog alfa [BAY 81-8973], 61.5%; and moroctocog alfa, 63.6%; Figure 1A ). In addition, another 20% of rFVIIIFc patients with severe disease were dosed every 3 days. In all patients in the cohort analysis, 82.5% and 76.5% were dosed ≤2×/week with rVIII-SingleChain and rFVIIIFc, respectively ( Figure 1B) . A further 8.5% of patients treated with rFVIIIFc were dosed every 3 days.
In the subgroup of patients with severe disease, median (mean) ABR values were 0.0 (0.3) for rVIII-SingleChain (n = 12), 0.0 (0.8) for rFVIIIFc (n = 20), 0.5 (1.1) for octocog alfa (rFVIII; n = 20), 1.0 (1.5) for octocog alfa (BAY 81-8973; n = 13), and 1.0 (1.4) for moroctocog alfa (n = 11), Table 2 . The differences among the products were not statistically significant (P = .1162) as shown by ANCOVA; however, the small sample size for each product likely played a role in this. When grouping products by type (long-acting products: rVIII-SingleChain and rFVIIIFc, n = 32; standard-acting products: octocog alfa (rFVIII), octocog alfa (BAY 81-8973), and moroctocog alfa, n = 44), an ad hoc ANCOVA showed P = .0262 for the difference between the two product types. Of these patients, the proportion with zero bleeds in numerical order was 75.0% for rVIII-SingleChain and 65.0% for rFVIIIFc, followed by the remaining three products where ≤50% of patients achieved zero bleeds (octocog alfa [rFVIII], 50.0%; octocog alfa [BAY 81-8973], 46.2%; and moroctocog alfa, 36.4%; P = .3089 comparing this proportion among the products, Table 2 ). When the two product types were compared instead of the products, a trend was seen in statistical significance (P = .0618). In addition, median annualized Table 2 ). In addition, median AsBR values were 0.0 across all products (means as shown in Table 2 , P = .0649), and the percentage of patients reporting zero spontaneous bleeds were rVIII-SingleChain, 92.5%; rFVIIIFc, 89.4%; octocog alfa (rFVIII), 82.8%; octocog alfa (BAY 81-8973), 77.5%; and moroctocog alfa, 70.0% (P = .0555, Table 2 ).
TA B L E 1 Baseline patient characteristics for patients included in the cohort analysis
Overall mean consumption in patients with severe disease using rVIII-SingleChain (n = 12) was 83. 
| Switch analysis
In patients treated with rVIII-SingleChain prophylaxis, 37 had data available for prior FVIII therapy and were included in the switch analysis. Overall, 97.3% (36/37) of patients were ≥12 years and 32.4% (12/37) of patients had severe disease. The average length of treatment on rVIII-SingleChain was 44 (range 8-78) weeks.
Of the 37 patients who had received prior treatment with FVIII products, the majority (75.7%) were treated with standard-acting rFVIII; 21.6% were treated with plasma-derived FVIII, and one patient (2.7%) was using a long-acting rFVIII product. Twenty-one (56.8%) patients were on prophylaxis with their prior drug, and all of them infused factor at least 3×/week before switching to rVIII-SingleChain.
After switching to prophylaxis with rVIII-SingleChain, 71.4% of these 21 patients were dosed ≤2×/week.
Prior to the switch, 16 (43.2%) patients were treating on-demand; after switching to prophylaxis with rVIII-SingleChain, the majority (78.4%) of the 37 patients were on a 2×/week dosing regimen ( Figure 3 ). After patients had switched from prophylaxis with their prior FVIII product to prophylaxis with rVIII-Sin-gleChain, mean ABRs were also somewhat reduced (0.7 vs 0.2) compared with the prior FVIII product (P = .0469, Table 3 ). In addition, the mean AsBR reduced from 0.3 with the prior therapy to 0.0 with rVIII-SingleChain (P = .0691, Table 3 ). Furthermore, the proportion of patients with zero bleeds (spontaneous or trauma-related) increased from 57.1% to 81.0% after switching to rVIII-SingleChain (P = .1167, Table 3 ), and the proportion of patients with zero spontaneous bleeds increased from 76.2% to 95.2% (P = .0027, Table 3 ).
For patients switching to rVIII-SingleChain, prophylactic consumption decreased in 18/21 patients, with a mean reduction of 32% (from 109.4 to 74.5 IU/kg) compared with prior FVIII products (P < .0001, Figure S1 ). Of the patients on a 2×/week regimen with rVIII-Sin-gleChain (n = 15), mean weekly consumption reduced from 115.1 to 66.0 IU/kg/week when switching from prior FVIII to rVIII-SingleChain (P < .0001). Furthermore, mean factor consumption reduced by 41.6%
(112.5 to 65.7 IU/kg, P < .0001) in patients (n = 13) who switched from a dosing frequency of 3×/week with prior FVIII to 2×/week with rVIII-SingleChain.
| D ISCUSS I ON
This study assessed real-world experience of rFVIII products in Germany through a retrospective review of patient chart data. In this cohort study, bleed rates were low and comparable between products; however, rVIII-SingleChain demonstrated lower mean consumption than the other commonly used products assessed, as well as similar dosing frequency to rFVIIIFc as the two long-acting products included in this analysis. disease. This suggests that the 2×/weekly regimen is an acceptable prophylactic regimen for many patients including those previously treated on-demand. Treatment burden is a major challenge when patients consider switching from on-demand to prophylaxis; however, switching to prophylaxis may be beneficial, as it may prevent morbidity associated with long-term joint damage resulting from recurrent bleeding. In addition, in those patients already receiving prophylaxis prior to switching to rVIII-SingleChain, the reduction in infusion frequency may reduce overall treatment burden, and the reduced consumption indicates potential economic benefit may ensue.
TA B L E 2 Bleeding rates in patients using rVIII-SingleChain and other FVIII products
Similar bleeding rates were observed among FVIII products in this analysis, and the low ABRs overall suggests bleeding risk was generally well managed. The cohort analysis shows that long-acting In addition, the switch analysis of the prophylaxis-to-prophylaxis treatment group demonstrated a 32% reduction in mean weekly factor consumption across all treatment regimens after patients switched to rVIII-SingleChain. As a result, in the patients who switched from prior product to rVIII-SingleChain, the expected annual consumption may reduce from 398,216 to 271,180 IU for a 70-kg patient. A previous study in the US found that patients switching from standard-acting products to long-acting products resulted in higher expenditure over 2 years; however, that analysis did not include rVIII-SingleChain. 11 Overall, in this analysis, rVIII-SingleChain was demonstrated to be effective, suggesting that this long-acting product provides a re- 
| CON CLUS ION
In conclusion, this is the first study evaluating the clinical benefits of a range of FVIII products using real-world data in Germany. This analysis suggests that patients, including those with severe disease, can be dosed less frequently using rVIII-SingleChain compared with standardacting products, which may reduce the burden of treatment. In this Abbreviations: ABR, annualized bleed rate; AsBR, annualized spontaneous bleed rate; SD, standard deviation.
TA B L E 3 Bleeding rates in patients who have switched from prophylaxis with their prior FVIII product to prophylaxis with rVIII-SingleChain analysis, patients treated with rVIII-SingleChain had the lowest factor consumption compared with other FVIII products. rVIII-SingleChain provides excellent bleeding protection with bleed rates comparable to those observed with other FVIII products. This analysis also demonstrates that rVIII-SingleChain provides effective bleed prevention in patients who switched to rVIII-SingleChain prophylaxis, allowing the majority of patients to be treated on a 2×/week regimen, and patients were able to reduce their factor consumption without compromising clinical outcome. Given the limitations of this study, further research with a larger sample, longer duration, and potentially more robust design is needed to confirm these results.
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